Marinus Pharmaceuticals (NASDAQ:MRNS) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday, December 30th.
MRNS has been the topic of a number of other research reports. JMP Securities reaffirmed an “outperform” rating and set a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th. Laidlaw started coverage on Marinus Pharmaceuticals in a research note on Thursday, December 14th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, ValuEngine lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
Marinus Pharmaceuticals (NASDAQ:MRNS) opened at $7.34 on Friday. Marinus Pharmaceuticals has a 52-week low of $1.06 and a 52-week high of $9.87.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.02.
In other Marinus Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv sold 1,272,547 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $7.88, for a total value of $10,027,670.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.40% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of the business. Susquehanna International Group LLP acquired a new stake in Marinus Pharmaceuticals in the 3rd quarter worth about $503,000. Iguana Healthcare Management LLC acquired a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at about $1,027,000. Perceptive Advisors LLC acquired a new position in shares of Marinus Pharmaceuticals in the 3rd quarter valued at about $8,527,000. Granite Point Capital Management L.P. lifted its stake in shares of Marinus Pharmaceuticals by 250.3% in the 3rd quarter. Granite Point Capital Management L.P. now owns 2,684,848 shares of the biopharmaceutical company’s stock valued at $15,760,000 after purchasing an additional 1,918,400 shares in the last quarter. Finally, Citadel Advisors LLC lifted its stake in shares of Marinus Pharmaceuticals by 327.8% in the 3rd quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 39,371 shares in the last quarter. 49.77% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded to “Buy” at BidaskClub” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/01/14/marinus-pharmaceuticals-mrns-upgraded-at-bidaskclub.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.